Although targeting HGF/c-MET has improved clinical outcomes in some cancers, monotherapy targeting HGF/c-MET has been unsuccessful in proving considerable clinical efficacy in several cancers (Fu J. et al., 2021). The gene discussed is MET; the disease is cancer.